Zhejiang Orient Gene Biotech (688298) Stock Overview

Zhejiang Orient Gene Biotech Co., Ltd. researches and develops, produces, and sells in vitro diagnostic products worldwide. The company offers IFA solutions, digital test, oral fluid test, and covid-19 test products; and immunological diagnosis product, such as hair drug test kit, monkeypox, saliva drug test, urine multi-drug test, urine single-drug test, rapid test, digital pregnancy test, male-fertility test, menopause test, and other test products. It also provides molecular diagnosis products, including nucleic acid extraction systems, real time PCR systems, virus detection kits, viral nucleic acid extraction kits, and general products; liquid biochip products; mini immunofluorescence analyzers, handheld fluorescence immunoassay analyzers, fluorescence immunoassay analyzers, handheld oral fluid drug test readers, colloidal gold test readers, and urine drug test cup readers; and dry biochemical strips comprising urine reagent strips, urine analyzers, alcohol test, and vaginal pH test products. In addition, the company offers raw materials for fertility, tumor and cardiac marker, drugs of abuse, infectious diseases, pet, antibody, and others; and FISH probes comprising solid tumor probes, chromosome test, hematologic disease probes, reagents, and instruments. Zhejiang Orient Gene Biotech Co., Ltd. was founded in 2005 and is based in Huzhou, China.